Skip to content.Skip to side navigation. Quick Navigation: Skip to content.Skip to side navigation.
GPO Access Home Page.
Jump to selected topic.
Navigation Bar
About.Help. A-Z Resource List. Locate a Federal Depository Library. Buy Publications. Legislative. Executive. Judicial.
National Archives and Records Administration logo.
Database Features.
Browse
Simple Search
Advanced Search
* Boolean
  * Proximity
Search History
Search Tips
Corrections

Latest Updates

User Info
FAQs
Agency List
e-CFR Main Page
Related Resources
Code of Federal Regulations
Federal Register
List of CFR
Sections Affected
Regulations.gov
Unified Agenda
All NARA Publications
About Government.
Ben's Guide Logo.
Get Adobe Reader

blue pill
e-CFR Data is current as of September 18, 2008


Title 21: Food and Drugs
PART 1—GENERAL ENFORCEMENT REGULATIONS
Subpart B—General Labeling Requirements

Browse Previous | Browse Next

§ 1.21   Failure to reveal material facts.

(a) Labeling of a food, drug, device, or cosmetic shall be deemed to be misleading if it fails to reveal facts that are:

(1) Material in light of other representations made or suggested by statement, word, design, device or any combination thereof; or

(2) Material with respect to consequences which may result from use of the article under: (i) The conditions prescribed in such labeling or (ii) such conditions of use as are customary or usual.

(b) Affirmative disclosure of material facts pursuant to paragraph (a) of this section may be required, among other appropriate regulatory procedures, by

(1) Regulations in this chapter promulgated pursuant to section 701(a) of the act; or

(2) Direct court enforcement action.

(c) Paragraph (a) of this section does not:

(1) Permit a statement of differences of opinion with respect to warnings (including contraindications, precautions, adverse reactions, and other information relating to possible product hazards) required in labeling for food, drugs, devices, or cosmetics under the act.

(2) Permit a statement of differences of opinion with respect to the effectiveness of a drug unless each of the opinions expressed is supported by substantial evidence of effectiveness as defined in sections 505(d) and 512(d) of the act.

Browse Previous | Browse Next


August 1, 2007

-->